搜索优化
Rewards
English
搜索
Copilot
图片
视频
地图
资讯
购物
更多
航班
旅游
酒店
房地产
笔记本
Top stories
Sports
U.S.
Local
World
Science
Technology
Entertainment
Business
More
Politics
过去 7 天
时间不限
过去 1 小时
过去 24 小时
过去 30 天
按时间排序
按相关度排序
1 天
Astria Therapeutics股票因OX40项目前景保持买入评级
周五,H.C. Wainwright维持对Astria Therapeutics (NASDAQ:ATXS)的买入评级,目标价格坚持在16.00美元。该公司的关注点集中在本周早些时候关于一种竞争性特应性皮炎(AD)治疗方法的最新进展上。安进公司宣布了其OX40抗体rocatinlimab在HORIZON试验中的初步第三期结果。 研究报告显示,rocatinlimab的表现优于安慰剂,达到了所有主要 ...
dermatologyadvisor
2 天
HORIZON: Rocatinlimab Effective in Adults With Atopic Dermatitis
Topline results were announced from a phase 3 trial evaluating rocatinlimab for the treatment of moderate to severe atopic dermatitis.
3 天
潜在首款!治疗特应性皮炎,安进单抗3期试验达双主要终点
特应性皮炎是最常见的湿疹类型,是一种慢性炎症性疾病,会导致皮肤过度干燥、瘙痒并伴有疼痛。中度至重度特应性皮炎患者会出现慢性症状,不可预测的发作会加剧症状,可能带来疼痛并扰乱日常生活。这些患者中几乎有一半报告出现严重瘙痒,导致反复抓挠,这会导致皮肤增厚 ...
3 天
Amgen: Pipeline Updates, Uplizna Performs And Rocatinlimab Underwhelms
Amgen's shares fell despite positive phase 3 results of rocatinlimab and Uplizna. It looks well-positioned for long-term ...
The Pharma Letter
3 天
Amgen updates underwhelm investors
Amgen's shares fell over 5% after updates on its Phase III immunology drug, rocatinlimab, raised investor concerns. While the ...
4 天
on MSN
Amgen stock slides 5% as analysts weigh in on drug study results (update)
Amgen (NASDAQ:AMGN) shares were down 5% Wednesday, the day after the company reported Phase 3 results for its drugs ...
4 天
Amgen's stock falls 4% as analysts say drug updates lag competitors
Amgen Inc.'s stock was down 4% Wednesday, after the company offered an update on two drugs in development, but analysts said neither look as effective as rival products from competitors.
4 天
Amgen's Rocatinlimab Has Commercial Potential Despite Competitive Landscape, Says Goldman Sachs
In an investor update on Tuesday, Amgen Inc (NASDAQ:AMGN) released data from Phase 3 trials of rocatinlimab and Uplizna ...
4 天
Amgen slips on eczema drug results
Amgen (AMGN) stock slid more than 4.5% at the start of Wednesday trading after the pharmaceutical giant reported the results ...
4 天
Amgen维持买入评级,股票目标价不变,管线更新引关注
周三,Truist Securities维持对Amgen (NASDAQ:AMGN)股票的买入评级,目标价保持在320.00美元不变。这一决定是在Amgen披露两个主要管线项目的积极Phase 3更新之后做出的。这些项目涉及用于治疗全身性重症肌无力(gMG)的Uplizna,以及用于治疗特应性皮炎的rocatinlimab,后者是ROCKET项目在该适应症上的首次结果。 Amgen于周二报告了这些 ...
4 天
Hold Rating on Amgen Amid Concerns Over Rocatinlimab and Uplizna Trial Results
Leerink Partners analyst David Risinger has maintained their neutral stance on AMGN stock, giving a Hold rating today. David Risinger has ...
BioSpace
4 天
Amgen Scores Late-Stage Wins in Eczema and Myasthenia Gravis, But Analysts See Mixed Results
Jefferies analyst Michael Yee in a note to investors called rocatinlimab’s atopic dermatitis data “modest,” noting that the ...
一些您可能无法访问的结果已被隐去。
显示无法访问的结果
反馈